Search company, investor...

abcarta

abcarta.com

Stage

Corporate Majority | Acquired

About abcarta

abcarta provides clinicopathological detection and diagnosis products and services for doctors, research institutions, and drug developers.

Headquarters Location

Building 2, Tengfei Innovation Park 388 Xinping St., Suzhou Industrial Park

Suzhou, Jiangsu,

China

+86 0512-88856999

Missing: abcarta's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: abcarta's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing abcarta

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

abcarta is included in 1 Expert Collection, including Digital Health.

D

Digital Health

13,587 items

abcarta Frequently Asked Questions (FAQ)

  • Where is abcarta's headquarters?

    abcarta's headquarters is located at Building 2, Tengfei Innovation Park, Suzhou.

  • What is abcarta's latest funding round?

    abcarta's latest funding round is Corporate Majority.

  • Who are the investors of abcarta?

    Investors of abcarta include Fosun Pharmaceutical, Xinyuyan Biotechnology, Tahoe Venture, JC Capital and BOHE Angel Fund.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.